(ICUI) ICU Medical - Overview
Sector: Healthcare | Industry: Medical Instruments & Supplies | Exchange: NASDAQ (USA) | Market Cap: 3.332m USD | Total Return: 3.5% in 12m
Avg Turnover: 37.4M
EPS Trend: 58.0%
Qual. Beats: 8
Rev. Trend: -5.9%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
No distinct edge detected
ICU Medical, Inc. (ICUI) specializes in the development and manufacturing of medical technologies for infusion therapy, vascular access, and vital care. Its product portfolio includes needle-free connectors, hazardous drug handling systems, intravenous (IV) solutions, and smart infusion pumps integrated with medication safety software. The company serves a global customer base spanning acute care hospitals, ambulatory clinics, and long-term care facilities.
The medical supply sector operates under high regulatory oversight and significant R&D requirements to ensure patient safety and device interoperability. ICU Medical utilizes a recurring revenue model by providing both durable infusion hardware and the high-volume consumables, such as IV sets and solutions, required for daily clinical operations.
Further analysis of the companys fundamentals on ValueRay can provide deeper insights into its market positioning. ICU Medical continues to focus on the integration of hardware and software to minimize medication errors in clinical settings.
- Consumable IV therapy product demand drives recurring revenue stability
- Integration of legacy Smiths Medical assets impacts consolidated operating margins
- Global hospital capital expenditure cycles influence infusion pump hardware sales
- Supply chain efficiency for high-volume saline and electrolyte solutions
- Regulatory compliance and product safety standards affect market share retention
| Net Income: 46.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA -1.21 > 1.0 |
| NWC/Revenue: 31.12% < 20% (prev 36.15%; Δ -5.03% < -1%) |
| CFO/TA 0.04 > 3% & CFO 167.4m > Net Income 46.3m |
| Net Debt (1.10b) to EBITDA (314.5m): 3.49 < 3 |
| Current Ratio: 2.30 > 1.5 & < 3 |
| Outstanding Shares: last quarter (25.2m) vs 12m ago 2.62% < -2% |
| Gross Margin: 36.36% > 18% (prev 0.35%; Δ 3.60k% > 0.5%) |
| Asset Turnover: 52.61% > 50% (prev 57.83%; Δ -5.22% > 0%) |
| Interest Coverage Ratio: 1.30 > 6 (EBITDA TTM 314.5m / Interest Expense TTM 84.2m) |
| A: 0.17 (Total Current Assets 1.19b - Total Current Liabilities 517.9m) / Total Assets 4.01b |
| B: 0.18 (Retained Earnings 721.0m / Total Assets 4.01b) |
| C: 0.03 (EBIT TTM 109.6m / Avg Total Assets 4.10b) |
| D: 0.35 (Book Value of Equity 671.6m / Total Liabilities 1.90b) |
| Altman-Z'' = 2.23 = BBB |
| DSRI: 1.10 (Receivables 201.1m/204.7m, Revenue 2.16b/2.42b) |
| GMI: 0.97 (GM 36.36% / 35.11%) |
| AQI: 1.07 (AQ_t 0.58 / AQ_t-1 0.54) |
| SGI: 0.89 (Revenue 2.16b / 2.42b) |
| TATA: -0.03 (NI 46.3m - CFO 167.4m) / TA 4.01b) |
| Beneish M = -3.04 (Cap -4..+1) = AA |
As of May 27, 2026, the stock is trading at USD 134.97 with a total of 308,747 shares traded.
Over the past week, the price has changed by +9.66%,
over one month by +9.87%,
over three months by -10.51% and
over the past year by +3.47%.
ICU Medical has received a consensus analysts rating of 4.33. Therefore, it is recommended to buy ICUI.
- StrongBuy: 3
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 174.2 | 29% |
P/E Trailing = 71.2888
P/E Forward = 16.3399
P/S = 1.5448
P/B = 1.5777
P/EG = 0.0756
Revenue TTM = 2.16b USD
EBIT TTM = 109.6m USD
EBITDA TTM = 314.5m USD
Long Term Debt = 1.26b USD (from longTermDebt, last quarter)
Short Term Debt = 34.2m USD (from shortTermDebt, last quarter)
Debt = 1.39b USD (from shortLongTermDebtTotal, last quarter) + Leases 45.2m
Net Debt = 1.10b USD (calculated: Debt 1.39b - CCE 288.3m)
Enterprise Value = 4.43b USD (3.33b + Debt 1.39b - CCE 288.3m)
Interest Coverage Ratio = 1.30 (Ebit TTM 109.6m / Interest Expense TTM 84.2m)
EV/FCF = 55.10x (Enterprise Value 4.43b / FCF TTM 80.4m)
FCF Yield = 1.81% (FCF TTM 80.4m / Enterprise Value 4.43b)
FCF Margin = 3.73% (FCF TTM 80.4m / Revenue TTM 2.16b)
Net Margin = 2.15% (Net Income TTM 46.3m / Revenue TTM 2.16b)
Gross Margin = 36.36% ((Revenue TTM 2.16b - Cost of Revenue TTM 1.37b) / Revenue TTM)
Gross Margin QoQ = 32.64% (prev 37.41%)
Tobins Q-Ratio = 1.10 (Enterprise Value 4.43b / Total Assets 4.01b)
Interest Expense / Debt = 6.07% (Interest Expense 84.2m / Debt 1.39b)
Taxrate = 21.0% (US default 21%)
NOPAT = 86.6m (EBIT 109.6m * (1 - 21.00%))
Current Ratio = 2.30 (Total Current Assets 1.19b / Total Current Liabilities 517.9m)
Debt / Equity = 0.66 (Debt 1.39b / totalStockholderEquity, last quarter 2.11b)
Debt / EBITDA = 3.49 (Net Debt 1.10b / EBITDA 314.5m)
Debt / FCF = 13.66 (Net Debt 1.10b / FCF TTM 80.4m)
Total Stockholder Equity = 2.12b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.13% (Net Income 46.3m / Total Assets 4.01b)
RoE = 2.19% (Net Income TTM 46.3m / Total Stockholder Equity 2.12b)
RoCE = 3.24% (EBIT 109.6m / Capital Employed (Equity 2.12b + L.T.Debt 1.26b))
RoIC = 2.45% (NOPAT 86.6m / Invested Capital 3.53b)
WACC = 8.27% (E(3.33b)/V(4.72b) * Re(9.71%) + D(1.39b)/V(4.72b) * Rd(6.07%) * (1-Tc(0.21)))
Discount Rate = 9.71% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 91.11 | Cagr: 1.90%
[DCF] Terminal Value 73.10% ; FCFF base≈102.0m ; Y1≈89.4m ; Y5≈72.3m
[DCF] Fair Price = 2.46 (EV 1.16b - Net Debt 1.10b = Equity 61.6m / Shares 25.0m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 58.04 | EPS CAGR: 8.36% | SUE: 1.17 | # QB: 8
Revenue Correlation: -5.93 | Revenue CAGR: -0.21% | SUE: -0.05 | # QB: 0
EPS current Quarter (2026-06-30): EPS=1.91 | Chg30d=-0.44% | Revisions=-11% | Analysts=6
EPS next Quarter (2026-09-30): EPS=2.08 | Chg30d=-3.03% | Revisions=-40% | Analysts=6
EPS current Year (2026-12-31): EPS=8.17 | Chg30d=+0.71% | Revisions=+33% | GrowthEPS=+5.3% | GrowthRev=-1.7%
EPS next Year (2027-12-31): EPS=9.33 | Chg30d=+1.40% | Revisions=+33% | GrowthEPS=+14.2% | GrowthRev=+4.6%
[Analyst] Revisions Ratio: -40%